English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Correspondence: C Kao Department of Molecular and Cellular Biochemistry, indiana University, Bloomington, iN 47405, USA Tel +1 812 855 7583 Fax +1 812 856 5710 email ckao@indiana.edu Abstract: Chronic infection by the hepatitis C virus (HCV) can lead to liver cirrhosis and hepatocellular carcinoma. There is currently no prophylactic vaccine against HCV, and the treatment is currently limited to modified interferon and ribavirin. The RNA-dependent RNA polymerase (RdRp) of HCV is an attractive target for inhibitor development, and this has led to active efforts in the development of nucleoside and non-nucleoside inhibitors. The HCV polymerase is also one of the model systems for detailed analysis of how RdRp structure affects the mechanism of RNA synthesis. This review summarizes current efforts with inhibitors targeting the HCV RdRp and how the various inhibitors affect the mechanism of RNA synthesis.

virus adaptation and treatment

An update on small molecule inhibitors of the HCV NS5B polymerase: effects on RNA synthesis in vitro and in cultured cells, and potential resistance in viral quasispecies